|Description||Avelumab is a human monoclonal antibody that is commonly used in immunotherapy and originally for non-small-cell lung carcinoma (NSCLC). It binds to the programmed death-ligand 1 (PD-L1) preventing the combination of PD-L1 and its receptor programmed cell death 1 (PD-1), which leads to the inhibition of CD8+ T cells. In January 2017 it received orphan drug designation by the European Medicines Agency for the treatment of gastric cancer; In March 2017, it was approved by FDA to treat patients with Merkel-cell carcinoma.|
|Brife Description||human monoclonal antibody, PD-L1, NSCLC, gastric cancer, Merkel-cell carcinoma|
|Application||the treatment of gastric cancer and Merkel-cell carcinoma|
|Shelf Life||2 years|
|Current Developer||EMD Serono (Merck KGaA), Pfizer|
Anti-PD-L1 monoclonal antibody BMS-936559 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance th...
A human immunoglobulin G1 (IgG1) monoclonal antibody binds to PD-L1 and prevents the interaction of PD-L1 with its receptor PD-1, with potential immune checkpoi...
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody. It was approved by FDA for the treatment of patients with locally advanced or metasta...
PD-1/PD-L1 Inhibitor 1
PD-1/PD-L1 Inhibitor 1, is an inhibitor of the PD-1 /PD-Ll protein/protein interaction.
Avelumab is a human monoclonal antibody that is commonly used in immunotherapy and originally for non-small-cell lung carcinoma (NSCLC). It binds to the program...
A first-in-class oral, small molecule antagonist of PD-L1, PD-L2 and V-region immunoglobulin-containing suppressor of T cell activation (VISTA).
A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibi...
PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1).